Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma

NCT03480256 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03480256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03480256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Unknown status
Start date
July 27, 2018
Completion date
August 31, 2020
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer